BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
During activation, T cells express receptors for receiving positive and negative costimulatory signals. Here we identify the B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BTLA inhibits T/B cell activation and the secretion of cytokines11”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“anti-BTLA crosslinking may also cause the phosphorylation of the Src-homology domain 2 (SH2)-containing proteins tyrosine phosphatase-1 (SHP-1) and SHP-2 to activate suppression signaling”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“Additionally, the western blotting demonstrated that crosslinked BTLA promotes the phosphorylation of SHP-1/2, consistent with findings from previous studies11,42, and also activates the PI3K-Akt-GSK-3β pathway in purified CD4+ T cells.”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“BTLA is the essential co‐signaling immune checkpoint protein with bidirectional functions [331].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [331]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“, and Y282 is similar to the immunoreceptor tyrosine-based switch motif (ITSM) in PD-1 (ref”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Chambers, C.A. et al. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol. 28, 3137–3143 (1998). · doi:10.1002/(sici)1521-4141(199810)28:10<3137::aid-immu3137>3.0.co;2-x
- Bachmann, M.F. et al. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur. J. Immunol. 31, 450–458 (2001). · DOI · Paper page
Cited by
Items 701–800 of 894
BTLA deficiency promotes HSC activation and protects against hepatic ischemia-reperfusion injury
Shen, X., Mai, R., Han, X., Wang, Q., Wang, Y., Ji, T., Tong, Y., Chen, P., Zhao, J., He, X.-Y., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000449 · Cited by 3
“[14,30] However, its function in liver IRI is still unclear.”
Use of Treated Corn Residues in Growing Diets
Peterson, S., Burken, D. B., Donald, J. C. M., & Erickson, G. E. (2014) · Lincoln (University of Nebraska) · Cited by 3
Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy ResistancePreprint
Maitituoheti, M., Shi, A., Tang, M., Ho, L., Terranova, C. J., Galani, K., Keung, E. Z.-Y., Creasy, C. A., Wu, M., Chen, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.31.506051 · Cited by 3
“, Yuan, S., Norgard, R.J., Yan, F., Yamazoe, T., Blanco, A., and Stanger, B.Z. (2020). Tumor 1161 Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer. Cancer immunology 1162 research 8, 282-291. 1163 1164 Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program…”
BackgroundInfluentialSelf-citationZhang, J., Zhong, X., Wang, S., & Wang, L. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01716-9 · Cited by 3
“In tumor cells, BTLA can inhibit the activation of lymphocytes, thereby facilitating the occurrence of immune evasion[24–26].”
BTLA-mediated regulation of neuroimmune responses enhances recovery after intracerebral hemorrhage
Wu, Y., Zhang, Y., Fu, P., Huang, M., Chen, S., Li, Y., Wu, T., Rastegar‐Kashkooli, Y., Cheng, N., Zhao, T., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03705-6 · Cited by 2
“BTLA, an inhibitory receptor expressed on most lymphocytes, helps to restrain excessive immune activation [55, 56].”
Nanobiotechnology for dendritic cell-based cancer immunotherapy
Li, R. H., Yi, W., Qian, X., Hu, S., Shen, H., Yan, D., & Li, Y. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100485 · Cited by 3
The role of the BTLA–HVEM complex in the pathogenesis of breast cancer
Hu, X. (2024) · Breast Cancer · doi:10.1007/s12282-024-01557-7 · Cited by 2
“This model demonstrated an increased susceptibility to auto-immune encephalomyelitis in the mice [62].”
Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies
Anvari, S., Nikbakht, M., Vaezi, M., Amini‐Kafiabad, S., & Ahmadvand, M. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03596-8 · Cited by 3
Cancer Immunotherapy with Vaccines and Checkpoint Blockade
Pardoll, D. M. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00052-4 · Cited by 3
Szymczak, M., Ziętkiewicz, S., Kuncewicz, K., Rodziewicz‐Motowidło, S., & Orlikowska, M. (2019) · Protein Expression and Purification · doi:10.1016/j.pep.2019.105450 · Cited by 2
Diethelm, P., Schmitz, I., Iten, I., Kisielow, J., Matsushita, M., & Köpf, M. (2022) · European Journal of Immunology · doi:10.1002/eji.202048569 · Cited by 2
Expression analysis of inhibitory B7 family members in Alzheimer’s disease
Sabaie, H., Tamimi, P., Gharesouran, J., Salkhordeh, Z., Asadi, M. R., Sharifi‐Bonab, M., Shirvani-Farsani, Z., Taheri, M. N., Sayad, A., & Rezazadeh, M. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01274-8 · Cited by 3
“Though, B and T lymphocyte attenuator (BTLA) was pro - posed as a B7-H4 receptor binding indirectly (Watanabe et al. 2003, Sedy et al., 2005).”
BackgroundCurrent Understanding of PCSK9 and Its Relevance to Cancer Prognosis and Immune Therapy: A Review
Mashhadi, M. H., Taheri, F., Irani, S., Mousavi, A. M., Mehri, A., & Javid, H. (2024) · Iranian journal of pathology · doi:10.30699/ijp.2023.1999459.3093 · Cited by 3
Adegoke, A., Thangavelu, G., Chou, T.-F., Petersen, M., Kakugawa, K., May, J. F., Joannou, K., Wang, Q., Ellestad, K. K., Boon, L., et al. (2024) · Open Biology · doi:10.1098/rsob.240178 · Cited by 2
Yang, M., Zheng, C., Yu, M., Yin, C. C., Tang, L., Zhang, C., Yu, P., Han, Q., Ma, Y., Li, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009841 · Cited by 3
Role of Co-inhibitory Molecules in Tumor Escape from CTL Attack
Norde, W. J., Hobo, W. A., & Dolstra, H. (2015) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-17807-3_2 · Cited by 2
Johnston, N. (2014) · Scholarship@Western (Western University) · Cited by 3
Demaria, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00011-7 · Cited by 2
Gurka, S., Worbs, S., & Kroczek, R. A. (2009) · Hybridoma · doi:10.1089/hyb.2009.0047 · Cited by 2
Bensussan, A., & Olive, D. (2005) · Cellular Immunology · doi:10.1016/j.cellimm.2005.08.004 · Cited by 2
Jin, C.-Y., Su, N., Hu, C., Shao, T., Ji, J., Qin, L.-L., Fan, D., Lin, A., Xiang, L., & Shao, J.-Z. (2021) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2021.104312 · Cited by 2
David, P., Westmeier, J., Drabczyk-Pluta, M., Werner, T., Ickler, J., Francois, S., Bayer, W., Sutter, K., del Rio, M., Rodríguez-Barbosa, J.-I., et al. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.836291 · Cited by 2
“Moreover, our results show that blocking the interactions between the ligand HVEM and its inhibitory receptors BTLA and CD160 represent an innovative immunotherapeutic strategy to reinvigorate the branch of the host adaptive immune response against viral infections and cancers.”
BackgroundInfluentialT cell receptor signaling pathways: New targets for herpes simplex virus
Cao, Y., Li, Y., Zhang, Y.-C., & Zhang, C. (2008) · Virologica Sinica · doi:10.1007/s12250-008-3000-5 · Cited by 2
“On the other hand, the co-inhibitory receptors, CTLA4 , PD1, and recently discovered BTLA(65) attenuate TCR signaling by mechanisms that are not-yet clear, perhaps via recruiting phosphatases, such as SHP-1, SHIP-1 and/or SHIP(2, 11, 19, 47, 49).”
BackgroundInfluentialKłudka-Sternik, M., Serafin, A., Darmochwał-Kolarz, D., Radej, S., Roliński, J., Leszczynska-Gorzelak, B., & Oleszczuk, J. (2011) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-010-0054-7 · Cited by 2
Perspectives on the Role of T Cell Negative Immune Checkpoint Receptors in Health and Disease
Fujita, T., Clements, D. M., Premeaux, T. A., & Ndhlovu, L. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_6 · Cited by 2
Adams, S., Bhardwaj, N., & O’Neill, D. W. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_11 · Cited by 2
Betterle, C., Zanchetta, R., & Presotto, F. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-517-6_13 · Cited by 3
Informatics and the immune system: the expanding IL-1 and B7 protein families
Grant, E. P., Coyle, A. J., & Gutierrez-Ramos, J.-C. (2003) · Seminars in Immunology · doi:10.1016/s1044-5323(03)00048-4 · Cited by 2
Stühler, V., Alemi, B., Rausch, S., Stenzl, A., Schwab, M. G., Schaeffeler, E., & Bedke, J. (2024) · World Journal of Urology · doi:10.1007/s00345-023-04721-4 · Cited by 1
“BTLA-deficient T cells exhibit increased proliferation [26].”
Role of miRNAs as epigenetic regulators of immune checkpoints in lung cancer immunity
Cánovas‐Cervera, I., Nácher-Sendra, E., Suay, G., Lahoz, A., García‐Giménez, J. L., & Mena, S. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.08.002 · Cited by 2
Management of In-transit Disease
O’Connor, M. H., Rhodin, K. E., Tyler, D. S., & Beasley, G. M. (2024) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2024.11.004 · Cited by 1
Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice
Gherardi, L., Aubergeon, L., Sayah, M., Fauny, J., Dumortier, H., & Monneaux, F. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s490573 · Cited by 1
The Function of B and T Lymphocyte Attenuator and Its Role in Transplantation
Ma, K., Han, H., Bao, Y., Chen, R., Yang, Y., & Shao, W. (2025) · Apmis · doi:10.1111/apm.70012 · Cited by 1
“Consistent with T cells, BTLA did not significantly influence B cell development, as evidenced by the normal lymphocyte growth observed in mice lacking BTLA [34].”
Peng, Y., Zhang, L., & Zhang, M. (2025) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.33044 · Cited by 1
“BTLA contains ITIM and ITSM motifs in its cytoplasmic domain, which can be phosphorylated to recruit SHP1/SHP2, ultimately inhibiting T cell function (Watanabe et al. 2003; Sedy et al. 2005; Gavrieli et al. 2003).”
Nishi, T., Hayakawa, K., Ikeda, K., Fujishiro, M., Kataoka, Y., Yamaji, K., Takamori, K., Tamura, N., Sekigawa, I., & Morimoto, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311323 · Cited by 1
“B-and T-lymphocyte attenuator (BTLA), a type I membrane protein belonging to the Ig superfamily that acts as a co-inhibitory receptor [6], is possibly involved in the pathogenesis of autoimmune diseases [7].”
Lu, P., 郭继华, & Jia, R. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105339 · Cited by 1
The impact of T cell exhaustion in hematopoietic stem cell transplantation
Li, Y., Guo, H., Zhang, Y., Chen, J., Zhong, L., Huang, X., & Li, Y. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05141-y · Cited by 1
“…cytotoxicity and cytokine production [28], and (6) BTLA, which interacts with its ligand herpesvirus entry mediator (HVEM) to recruit the phosphatases SHP-1/SHP-2 to attenuate T cell receptor signaling and proliferation, thereby maintaining lymphocyte tolerance and limiting immunopathology [29].”
Spatial ecology of breast cancer reveals co-evolution of proliferative and dormant niches
Celik, C., Weston, W. A., Moraes-Lacerda, T., Withnell, E., Shi, P., Chu, T. M., Labbadia, J. P., Barr, A. R., & Secrier, M. (2026) · Genome Medicine · doi:10.1186/s13073-026-01711-0 · Cited by 1
“5b), potentially reflecting engagement of inhibitory immune signalling pathways in slower cycling cells [98, 99].”
Co-Receptors in the Positive and Negative Regulation of T-Cell Immunity
Schneider, H., & Rudd, C. E. (2008) · Springer eBooks · doi:10.1007/978-4-431-73884-8_8 · Cited by 1
Lindvall, T., Nandakumar, K. S., Yousefi, K. M., Holmdahl, R., & Andersson, Å. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.04.001 · Cited by 1
“It has been reported that loss of BTLA function leads to increased susceptibility to EAE (Watanabe et al., 2003 ).”
BackgroundLand, W. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-78655-1_8 · Cited by 1
Thangavelu, G., & Anderson, C. C. (2011) · Chimerism · doi:10.4161/chim.15083 · Cited by 1
Karabon, L., & Frydeck, I. (2012) · InTech eBooks · doi:10.5772/28160 · Cited by 2
“BTLA-deficient mice exhibit a moderate increase in specific antibody responses and increased susceptibility to experimentally induced autoimmune encephalomyelitis (EAC) (Watanabe et al, 2003).”
BackgroundT Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer
Ott, P. A., & Hodi, F. S. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-21167-1_10 · Cited by 1
Yang, B., Zhang, J., Li, L., Lyu, X., Wei, W., Huang, Z., Cai, B., & Wang, L. (2017) · Oncotarget · doi:10.18632/oncotarget.20644 · Cited by 1
“…glycoprotein D for HVEM, a receptor expressed on T lymphocytes)acts as a ligand and binds to HVEM to stimulate inflammation [6, 7], whereas the engagement between HVEM and B and T lymphocyte attenuator (BTLA), a member of the immunoglobulin superfamily, mediates inhibitory signaling pathway [8].”
Wu, C.-Y., Yang, H., & Haung, J.-L. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-eular.1102 · Cited by 1
“REFERENCES: [1] Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME (2012) Lupus nephritis: a critical review.”
BackgroundInfluentialAB0194 BTLA EXPRESSION IS REDUCED ON SLE B CELL SUBSETS
Wiedemann, A., Stefanski, A., Lino, A. C., & Dörner, T. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-eular.4091 · Cited by 1
“REFERENCES: [1] Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME (2012) Lupus nephritis: a critical review.”
BackgroundInfluentialCheckpoint inhibition in the fight against cancer: NK cells have some to say in it
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., & Gonzalez, S. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00013-8 · Cited by 1
The Role of Immune Checkpoints in Cancer Progression
Prasetya, R. A., & Wulansari, D. D. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105628 · Cited by 1
Chen, J., Wang, J., Liu, R., Xiong, H., Liu, Y., Zha, M., Li, Q., Liu, X., Shang, M., & Li, Y. (2022) · Medicine · doi:10.1097/md.0000000000029610 · Cited by 1
B7 Family Molecules in the Placenta
Petroff, M. G. (2007) · Springer eBooks · doi:10.1007/0-387-34944-8_15 · Cited by 1
Generation and Gene Expression of CD28-CD8 T-cells in Human
Weng, N. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9063-9_17 · Cited by 1
“PD-1 and BTLA are both expressed on T and B cells and serve as inhibitory receptors [35, 36 ].”
BackgroundThe role of inducible co-stimulator (ICOS) in immunodeficiency
Broides, A., & Conley, M. E. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.07.008 · Cited by 1
Immunosuppression: learning from the masters
Benedict, C. A., & Janssen, E. M. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.5.659 · Cited by 1
Attenuation of Immune Suppression to Complement Glioma Immunotherapy
Field, C. S. (2016) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17013761 · Cited by 1
Co-stimulation Regulation of Immune Tolerance and Autoimmunity
Dong, C., Nurieva, R., & Martín‐Orozco, N. (2007) · Springer eBooks · doi:10.1007/978-0-387-36003-4_7 · Cited by 1
Contribution of B7-H1/PD-1 Co-inhibitory Pathway to T-Cell Dysfunction in Cancer
Yao, S., & Chen, L. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3_3
“The current members of receptors include CD28, cytotoxic T-lymphocyte antigen-4 (CTLA-4), inducible costimulator (ICOS), program death 1 (PD-1) and B and T-lymphocyte attenuator (BTLA) (Watanabe et al., 2003).”
BackgroundBTLA (C272) expression on CD4+ T cells in Behçet patients
İlhan, F., Demir, N., Demır, T., & Gödekmerdan, A. (2012) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1105-32
“Th e inhibitory signals formed by CTLA-4 are highly important in the early phases of T cell response, while inhibitory signals through PD-1 and BTLA pathways, in addition to other receptors, gain importance in the later immune response.”
BackgroundInfluentialChauvin, C. (2007) · OpenGrey (Institut de l'Information Scientifique et Technique)
Inman, B. A., Frigola, X., Dong, H., Yang, J. C., & Kwon, E. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-332-5_21
Self-citationInhibitory Receptors and Autoimmunity in the Mouse
Clatworthy, M. R., & Smith, K. G. C. (2007) · Elsevier eBooks · doi:10.1016/b978-012369454-6/50090-x
Coca, R. C. (2011) · Institutional Repository of the University of Granada (University of Granada)
The role of HVEM-LIGHT stimulatory signals in intestinal inflammation
Schär, C. (2010) · Infoscience (Ecole Polytechnique Fédérale de Lausanne) · doi:10.3929/ethz-a-006416407
Rios, W. M. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2013.tde-22112013-101030
Bedin, M. R. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2013.tde-27092013-123929
Santana, V. C. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2014.tde-23092014-091246
Moll, T. (2004) · Archive ouverte UNIGE (University of Geneva) · doi:10.13097/archive-ouverte/unige:306
MURPHY, K. M. M., & Gillanders, W. E. (2011) · Defense Technical Information Center (DTIC) · doi:10.21236/ada545725
Self-citationReactive Oxygen Species – Key Immune Mediators in Type 1 Diabetes
Padgett, L. E., Burg, A. R., & Tse, H. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-30018-9_209
Diniz, M. O. (2010) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.87.2010.tde-25022011-142208 · Cited by 1
Role of the Hedgehog receptor Patched1 in the development and function of T lymphocytes
Michel, K. D. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3888
T-cell costimulation in graft-versus-host disease and graft-versus-leukemia effect
Yu, X., & Anasetti, C. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416004-0.00010-0
Breaking T-cell tolerance in chronic lymphocytic leukaemia
Wong, R. (2013) · ORCA Online Research @Cardiff (Cardiff University)
Rios, W. M. (2009) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2009.tde-17082013-095343
Immunomodulatory Molecules of the Immune System
Saenger, Y. M., Jenq, R. R., & Perales, M. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_5
Effects of Regulatory T Cell–Dendritic Cell Interactions on Adaptive Immune Responses
Bopp, T., Probst, H. C., Radsak, M. P., Schmitt, E., Stassen, M., Schild, H., & Tenzer, S. (2014) · Springer eBooks · doi:10.1007/978-3-319-05104-8_3
Regulation of immune response by T cell co-signaling
Abe, R. (2005) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.28.21
Preface to 2009 EURING Analytical Meeting proceedings
Bernardinis, B. D. (2012) · Journal für Ornithologie · doi:10.1007/s10336-012-0830-6
Personal glimpses of Robert A. Good
Oxelius, V. (2007) · Immunologic Research · doi:10.1007/s12026-007-0008-0
Regulation of transplantation tolerance by antigen-presenting cells
Gorczynski, R. M. (2005) · Transplantation Reviews · doi:10.1016/j.trre.2005.09.001
“[37] Watanabe N, Gavrieli M, Sedy JR, et al.”
BackgroundBusick, R. Y., Yammani, R. D., & Alexander‐Miller, M. A. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0377oc
“Previous reports have identified several receptors involved/associated with negative regulation of CD81 T cells, including lymphocyteactivation gene 3 (9), 2B4 (10), cytotoxic T-lymphocyte-associated protein 4 (11), paired immunoglobulin-like receptor B, GP49 (12), natural killer receptor G2a (13), B- and T-lymphocyte…”
BackgroundThe vignette for the V13N6 issue
Lai, M. M. C. (2006) · Journal of Biomedical Science · doi:10.1007/s11373-006-9119-1
“B and T lymphocyte attenuator (BTLA) is the third inhibitory receptor on T cells reported, which is believed to be involved in suppressing lymphocyte activation [22].”
BackgroundB7-H4 expression and increased death risk of cancer patients: A meta-analysis
Jiang, J., Wu, C., Zheng, X., Zhao, Y., Xu, B., Lu, B., & Shen, Y. (2011) · Clinical Oncology and Cancer Research · doi:10.1007/s11805-011-0586-4
The role of B7-H4 in islet transplantation
Wang, X. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0072087
Supplementary Issue: Gene and Protein Expression Profiling in Disease
Lomas, J. L. (2015)
Neurologie, A. A., & Weller, M. (2005) · Cited by 1
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals
Hanif, J. K. (2011) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/47574
“3.1 Monitoring expression of PD-L1, PD-L2, and B7-H4 on Transduced BM cell lines 50 3.2 Sequential transduction of HOXB4 BM cells....................................................... 50 3.3 Overexpression of PD-L1, PD-L2 and, B7-H4 on BM-derived DCs doesn’t interfere with DC development .............................…”
BackgroundInfluentialNovel Targets of Immune Inhibitory and Stimulatory Co-signals
Tamada, K. (2016) · Springer eBooks · doi:10.1007/978-4-431-55031-0_20
Releasing the Brakes in Cancer
Dubey, S., & Garg, A. (2016) · Journal of Bioanalysis & Biomedicine · doi:10.4172/1948-593x.1000147
“ICOS: Inducible costimulator of T cells [67] ,CTLA-4: Cytotoxic T Lymphocyte Antigen 4 [68], PD-1: Programmed Death 1 [69], BTLA: B and T Lymphocyte Attenuator [70], LAG-3: Lymphocyte Activation Gene [71], VISTA: V -domain Ig Suppressor of T cell Activation [72], OX-40: CD134 [73], 4-IBB: CD137 [74], GITR: Glucocortic…”
BackgroundYi, E. S. (2015) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000274
“Known co-stimulatory receptors include CD27, CD28, CD40, CD137, GITR, and OX-40 (CD134) that will promote the T-cell response [5-15].”
BackgroundCariri, F. A. M. O. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.87.2014.tde-08122014-110509
Identification of a role for B7-H4 in neutrophil homeostasis and innate immunity
Augustine, M. M. (2014)
Secondary Somatic Mutations in ETV6-RUNX1 Acute Lymphoblastic Leukemia Pathogenesis
Leon, M. A. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma
Iñarrairaegui, M., D’Avola, D., & Sangro, B. (2017) · Springer eBooks · doi:10.1007/978-3-319-64958-0_4
Effects of Subcutaneous Adipose Tissue on Metabolic Health in Obesity
Pelt, D. W. V. (2017) · Deep Blue (University of Michigan)
Metadata
- Authors
- Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., Murphy, T. L., Russell, J. H., Allison, J. P., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Boehringer Ingelheim (Germany) (DE)
- University of Perugia (IT)
- Washington University in St. Louis (US)
- Corresponding author
- Murphy, Kenneth M
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-06-08
- Volume
- 4
- Issue
- 7
- Pages
- 670-679
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2118705059
- Cited by
- 883
- References
- 52
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 38 · 2023: 38 · 2022: 38 · 2021: 59 · 2020: 56 · 2019: 49 · 2018: 35 · 2017: 29 · 2016: 31 · 2015: 36 · 2014: 34 · 2013: 41 · 2012: 37
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- BTLA, inhibitory receptors, T cell costimulation, CTLA-4, PD-1, SHP-1, SHP2, tyrosine phosphorylation, interleukin-2, T helper cell differentiation, B7 ligands, T cell proliferation, experimental autoimmune encephalomyelitis, antibody response
- MeSH terms
- Abatacept, Amino Acid Sequence, Animals, Antigens, Differentiation, Antigens, Surface, Encephalomyelitis, Autoimmune, Experimental, Interleukin-2, Lymphocyte Activation, Molecular Sequence Data, Phosphorylation, Proteins, Receptors, Immunologic, RNA, Messenger, T-Lymphocytes, Antigens, CD, Protein Tyrosine Phosphatases, B7-1 Antigen, Immunoconjugates, Intracellular Signaling Peptides and Proteins, Apoptosis Regulatory Proteins, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatase, Non-Receptor Type 11, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.